Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1948127 | 0.81 | SPHK2 (0.45) | GAAKDM4EHPGD | |
| SCHEMBL1944614 | 0.80 | MMP1 (0.51) | — | |
| SCHEMBL13058919 | 0.79 | RAB9A (0.59) | SMN1; SMN2KMT2ARAB9ATSHRKDM4E | |
| SCHEMBL1442608 | 0.77 | RAB9A (0.70) | GAASMN1; SMN2KMT2ARAB9ATSHR | |
| SCHEMBL1945585 | 0.77 | RAB9A (0.54) | GAASMN1; SMN2KMT2ARAB9AHPGD | |
| SCHEMBL1672799 | 0.77 | TSHR (0.55) | POLBSMN1; SMN2KMT2ARAB9ATSHR | |
| SCHEMBL1946591 | 0.77 | ALDH1A1 (0.50) | KDM4EHPGD | |
| SCHEMBL3275319 | 0.76 | RAB9A (0.68) | GAASMN1; SMN2KMT2ARAB9ATSHR | |
| SCHEMBL30182835 | 0.72 | RAB9A (0.69) | POLBGAASMN1; SMN2P2RY12KMT2A | |
| SCHEMBL13058939 | 0.71 | RAB9A (0.67) | POLBGAASMN1; SMN2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, ABCG2, TALDO1 | POLB 2744/4885GAA 1464/4885SMN1; SMN2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.